Century Therapeutics, Inc. (IPSC) vs MacroGenics, Inc. (MGNX)
A side-by-side comparison of Century Therapeutics, Inc. and MacroGenics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
IPSC
Century Therapeutics, Inc.
$1.32HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
MGNX
MacroGenics, Inc.
$3.64HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — IPSC vs MGNX
growth of $100 · dividends reinvested · last 5yIPSC -93.5% (-42.1%/yr)MGNX -81.6% (-28.7%/yr)MGNX compounded faster over this window
IPSC MGNX
IPSC vs MGNX: by the numbers
- •IPSC is the larger company ($239M vs $231M market cap).
Metrics side by side
Valuation
| Metric | IPSC | MGNX |
|---|---|---|
| P/S ratio | N/A | 1.38 |
| P/B ratio | 1.03 | 5.40 |
Profitability
| Metric | IPSC | MGNX |
|---|---|---|
| Gross margin | 88.00% | 71.12% |
| Operating margin | -13.78% | -48.72% |
| Net margin | -8.78% | -8.70% |
| ROE | -47.25% | -34.04% |
| ROIC | -43.69% | -16.87% |
Growth (annualized)
| Metric | IPSC | MGNX |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 7.33% |
| Total return CAGR (5Y) | -42.05% | -28.42% |
Frequently asked
- How have IPSC and MGNX total returns compared?
- Over the past 5 years, IPSC delivered -42.05% and MGNX delivered -28.42% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.